Latest Biotech News

Insilico Medicine announced ISM5059, a peripheral‑restricted NLRP3 inhibitor, as its nominated preclinical candidate and highlighted its presence at WHX 2026 to showcase partnerships bridging the...

Researchers at Spain’s CNIO and CIEMAT described a CRISPR‑based gene‑editing technique that targets tumors with amplified oncogenes, exploiting copy‑number vulnerabilities to selectively impair...

Scientists developed a mussel‑inspired bioadhesive patch that selectively targets and eliminates glioblastoma cells in preclinical models, offering a novel local therapeutic approach for an...

Formation Bio outlined its AI‑native, hub‑and‑spoke model for accelerating clinical development, combining an integrated execution engine and $600M+ of capital to speed trials and regulatory...

Telehealth provider Hims began marketing a compounded, pill-form version of Novo Nordisk’s Wegovy and similar GLP-1 therapies, sparking immediate regulatory and legal pushback. Novo and other...

The White House launched TrumpRx, a direct‑to‑consumer drug‑pricing hub built on GoodRx technology that displays cash prices and routes consumers to purchase options. The platform opened with a...

Biotech IPO activity accelerated this week with several drug developers tapping public markets. Eikon Therapeutics priced an upsized offering that raised approximately $381 million to advance its...

Generate:Biomedicines filed to go public, positioning its AI‑driven antibody programs — including an anti‑TSLP candidate in Phase 3 — for further clinical funding. The Flagship‑founded company...

Bayer reported Phase 3 results showing its Factor XIa inhibitor asundexian lowered the risk of secondary ischemic stroke by 26% without increasing bleeding, positioning the oral agent as a...

uniQure halted mid‑ and high‑dose cohorts in its AAV gene‑therapy trial for Fabry disease after two patients experienced grade‑3 liver enzyme elevations. The company reported the safety events and...

Adaptive Biotechnologies forecasted at least 20% MRD revenue growth for 2026, driven by ClonoSeq uptake, EMR integrations, and broader clinical endorsement of minimal residual disease as a...

A Nature Communications study identified succinate receptor 1 (SUCNR1) as a metabolic sentinel that limits blood cell formation and impedes acute myeloid leukemia (AML) progression. The...

Researchers reported a mussel‑inspired bioadhesive patch that selectively adheres to glioblastoma tissue and delivers cytotoxic agents to eliminate tumor cells in preclinical models. The platform...

Insilico Medicine announced ISM5059, a peripheral‑restricted NLRP3 inhibitor, as a nominated preclinical candidate following AI‑driven design and preclinical validation. The company emphasized the...

UniQure paused mid- and high-dose cohorts in its AAV gene‑therapy study for Fabry disease after patients developed dose-limiting liver toxicities. The company reported grade‑3 liver enzyme...

The White House launched TrumpRx, a direct‑to‑consumer drug purchasing platform that lists cash prices and discounts for a limited slate of medicines, but early reports show minimal impact on...

Telehealth provider Hims & Hers began offering a compounded oral version of Novo Nordisk’s Wegovy, prompting Novo to threaten legal action and the FDA to signal enforcement against unapproved...

Bayer reported Phase 3 data showing its Factor XIa inhibitor asundexian reduced secondary ischemic stroke risk by about 26% without increasing major bleeding, positioning the oral anticoagulant as...

Eikon Therapeutics completed an upsized $381 million IPO to bankroll clinical development of its oncology pipeline, including its TLR7/8 co‑agonist EIK‑1001 and PARP‑focused programs. The company,...

Illumina reported flat full‑year revenue for 2025 but flagged a notable acceleration in clinical sequencing consumables and an uptick in NovaSeq X placements. Management pointed to demand in...